Navigation Links
Viralytics Full Year Financial Results
Date:9/3/2013

SYDNEY, Sept. 3, 2013 /PRNewswire/ -- Viralytics Limited (ASX:VLA, OTCQX:VRACY) has released its financial results for the year ended 30 June 2013. 

 Financial ResultsNet cash used in operating activities for the Year

$3.9 millionCash position at the end of the Year

$5.1 millionReported loss

$4.1 million 

Operational HighlightsCAVATAK™ Phase II CALM Melanoma Clinical Trial (USA) Highlights include:

  • CAVATAK™ presented at the American Society of Clinical Oncologists conference in June 2013 and the World Melanoma Congress in July 2013 to a global oncology audience.
  • Key milestone achieved with enrolment of the 35th patient. Independent Data Monitoring Committee reported that CAVATAK™ had met safety and tolerability criteria.
  • Patient enrolment now at 10 prestigious US cancer clinics, with acceleration since early 2013. Aiming for full recruitment by the end of the calendar year.
  • 23 patients have reached assessment point against the trial's primary endpoint of immune related Progression Free Survival (irPFS) at 6 months. Interim results very promising with 8 of 23 patients having achieved the primary endpoint. Trial target is 10 of 54 evaluable patients achieving primary endpoint.
  • 2 complete and 6 partial tumour responses from 30 assessable patients. Anti-cancer activity demonstrated in non-injected (metastatic or secondary) as well as the injected tumours.
  • CAVATAK™ Phase I studies completed (Australia)

  • Intravenously administered CAVATAK™ well tolerated in late stage cancer patients.
  • Some evidence of tumour stabilization in intravenous study after only a single dose.
  • Sound basis for a multi-dose intravenous Phase 1 / 2 trial (our STORM study).
  • CAVATAK™ Preclinical studies completed (A
    '/>"/>

    SOURCE Viralytics Ltd.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2013 Financial Results
    2. International Isotopes Inc. Announces Second Quarter and Six Months 2013 Financial Results
    3. ULURU Inc. Reports Second Quarter 2013 Financial Results
    4. Tengion Provides Business Update and Reports Second Quarter 2013 Financial Results
    5. EntreMed Reports Second Quarter 2013 Financial Results
    6. Savient Pharmaceuticals Reports Second Quarter 2013 Financial Results
    7. Sinovac Reports Unaudited Second Quarter 2013 Financial Results
    8. Vasomedical Announces Financial Results for the Second Quarter of 2013
    9. Nephros Reports Second Quarter 2013 Financial Results
    10. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
    11. Dynasil Corporation of America Reports Third Quarter Fiscal 2013 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/25/2014)... , July 25, 2014  Semler Scientific, ... emerging medical risk assessment company that develops patented ... and evaluating chronic diseases, today reported financial results ... June 30, 2014. "The second ... Semler," said Doug Murphy-Chutorian , M.D., chief ...
    (Date:7/25/2014)... SAN DIEGO , July 25, 2014  Arena ... it will provide a corporate update and report second ... Market opens on Friday, August 1, 2014. That same ... at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). ... by dialing 877.643.7155 for domestic callers and 914.495.8552 for ...
    (Date:7/24/2014)... , July 24, 2014  Parnell Pharmaceuticals ... compounds that will be added to Parnell,s already ... CIMTECH Pty Ltd, a biotechnology company. The compounds ... have shown promise in bone regeneration and dermal ... develop the compounds for the veterinary market with ...
    Breaking Medicine Technology:Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4
    (Date:7/27/2014)... 27, 2014 The European Bromine market report ... and forecast of revenue. , Bromine market in European region ... and UK. Germany and France that forms a dominant share ... derivatives in Europe. , Browse through the TOC of ... the in-depth analysis provided Browse through the TOC of the ...
    (Date:7/27/2014)... Australia (PRWEB) July 27, 2014 ... in Australia is restricted to two companies, heavy ... to IBISWorld industry analyst Spencer Little, “Demand for ... due to rising health concerns, frequent anti-smoking campaigns, ... result, industry revenue is estimated to fall at ...
    (Date:7/27/2014)... 2014 iFitDress.com, a well-known wedding dress ... of wedding gowns with sleeves . Furthermore, it ... they are now available with big discounts, from 20 ... that iFitDress.com is one of the big players in ... the new wedding gowns feature fine craftsmanship and charming ...
    (Date:7/27/2014)... Alta Resources , a global provider of ... brands, announced today that it plans to fill more ... Florida and the Philippines. , A majority of the ... seasonal ramp-ups that require additional staffing in preparation for ... 2015. As more consumers become eligible for health-plan coverage ...
    (Date:7/27/2014)... Individuals that have been involved in an ... the newly released ebook guide for how to ... help those struggling through the aftermath of personal injury due ... guide attempts to help individuals understand the legal process and ... of their doctors and an experienced attorney. , Contact ...
    Breaking Medicine News(10 mins):Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Discounted Wedding Gowns With Sleeves Offered At iFitDress.com 2Health News:Alta Resources to Fill Approximately 2,500 Positions 2Health News:Alta Resources to Fill Approximately 2,500 Positions 3Health News:Auto Accident Personal Injury Ebook Guide Released by The Jones Firm 2
    ... In some cases, an apple a day may keep the ... may also do the job. A new study by ... the use of Aspirin as a preventative measure for cardiovascular ... collected data from clinical trials that looked at whether taking ...
    ... 5 (HealthDay News) -- Small rural hospitals in the United ... patient outcomes than larger hospitals, a new study finds. ... beneficiaries in order to assess the care provided by critical ... care beds and are located more than 35 miles from ...
    ... ROCHESTER, Minn. For nearly two decades, the medical ... lightning-rod topic of stem cells, in particular the controversy ... years ago successfully "reprogrammed" adult body cells to become ... over. Those redirected cells, known as induced pluripotent cells, ...
    ... HealthDay Reporter , TUESDAY, July 5 (HealthDay News) ... for easing low back pain in the short term, a ... mostly middle-aged, female and white, all of whom had chronic ... of either relaxation massage or structural massage were better able ...
    ... More breast cancer patients than previously believed may ... of Michigan Comprehensive Cancer Center study shows. Researchers ... whether cancer patients receive appropriate care and found that ... cancer patients undergo radiation treatments. The Surveillance ...
    ... Society invites you to attend the 2012 Symposium on ... held March 12-14, 2012, at the Marriott Baltimore Waterfront ... exciting first-time event. The symposium aims to bring ... and practice realms of the health-care community and to ...
    Cached Medicine News:Health News:Higher daily dose of aspirin could play key role in preventing heart attacks for those with diabetes 2Health News:Small, Rural Hospitals Provide a Lower Quality of Care: Study 2Health News:Moving beyond embryonic stem cells: Encouragement on the horizon 2Health News:Massage Beats Meds for Lower Back Pain, Study Says 2Health News:Radiation rates for breast cancer may be underestimated, U-M study finds 2Health News:HFES sponsors 2012 Symposium on Human Factors and Ergonomics in Health Care 2
    ... detection and semi-quantitation of ... antigen in serum as ... diagnosis of autoimmune disease. ... performed either manually or ...
    ... for the detection and quantitation ... nuclear antigens (ENA) [RNP, Sm, ... in human serum. SS-A (Ro) ... in the diagnosis of SLE, ...
    ... Enzyme-linked immunosorbent assays for ... IgG antibodies to extractable nuclear ... human serum. SS-A (Ro) and ... the diagnosis of SLE, subacute ...
    ... Inc. ENA Screen ELISA test system is ... antibodies to extractable nuclear antigens (anti-ENA) in ... directional insert, this test system is capable ... such as those against Jo-1, Sm, Sm/RNP, ...
    Medicine Products: